Compare · AURA vs MRNA
AURA vs MRNA
Side-by-side comparison of Aura Biosciences Inc. (AURA) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AURA and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $61.59B, about 79.9x AURA ($770.5M).
- Over the past year, AURA is up 18.0% and MRNA is up 537.5% - MRNA leads by 519.5 points.
- Both names hit the wire about 15 times in the past 4 weeks.
- MRNA has more recent analyst coverage (25 ratings vs 11 for AURA).
- Company
- Aura Biosciences Inc.
- Moderna Inc.
- Price
- $7.43+3.34%
- $154.14+9.79%
- Market cap
- $770.5M
- $61.59B
- 1M return
- +5.69%
- +179.70%
- 1Y return
- +18.02%
- +537.47%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2018
- News (4w)
- 15
- 15
- Recent ratings
- 11
- 25
Aura Biosciences Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The company also develops AU-011 in additional ocular oncology indications, including choroidal metastases. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest AURA
- Chief People Officer Person Julie was granted 107,611 shares (SEC Form 4)
- Chief Reg. & Quality Officer Kratz Erica was granted 100,885 shares (SEC Form 4)
- Chief Medical Officer Hopkins Janet Jill was granted 58,850 shares, increasing direct ownership by 18% to 380,190 units (SEC Form 4)
- SVP, Finance & PAO Elazzouzi Amy was granted 23,540 shares, increasing direct ownership by 20% to 143,600 units (SEC Form 4)
- Chief Operating Officer Abu-Absi Susan was granted 134,513 shares (SEC Form 4)
- SEC Form S-8 filed by Aura Biosciences Inc.
- Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- SEC Form EFFECT filed by Aura Biosciences Inc.
- SEC Form 3 filed by new insider Person Julie
- SEC Form 3 filed by new insider Kratz Erica
Latest MRNA
- Moderna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Moderna to Present at Upcoming Conferences in September 2026
- President Hoge Stephen converted options into 2,048 shares and covered exercise/tax liability with 991 shares, increasing direct ownership by 0.07% to 1,484,905 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.77% to 74,129 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.85% to 67,004 units (SEC Form 4) to satisfy withholding obligation
- Moderna upgraded by Argus with a new price target
- Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
- Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
- Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
- A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity